Biotechs Need To Work Harder To Grab What Capital Remains, E&Y Reports
Executive Summary
Biotechs fared better than expected in 2009, but the market still is not healthy. In the U.S., 20 percent of companies raised 78.5 percent of the capital, widening the already vast gap between the "have" and "have nots," Ernst & Young notes in its annual Beyond Borders report